BI Asset Management Fondsmaeglerselskab A S Raises Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

BI Asset Management Fondsmaeglerselskab A S boosted its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 362.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,493 shares of the company's stock after buying an additional 66,228 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Dr. Reddy's Laboratories were worth $1,334,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in shares of Dr. Reddy's Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc increased its holdings in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after buying an additional 1,600 shares in the last quarter. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares during the period. Farther Finance Advisors LLC increased its stake in Dr. Reddy's Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after purchasing an additional 2,093 shares in the last quarter. Finally, Independence Bank of Kentucky raised its holdings in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock worth $44,000 after purchasing an additional 2,220 shares during the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Price Performance

Shares of RDY stock traded up $0.15 during mid-day trading on Monday, reaching $13.94. The stock had a trading volume of 367,295 shares, compared to its average volume of 1,465,165. The company has a market cap of $11.63 billion, a P/E ratio of 22.17 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The business has a 50-day simple moving average of $13.17 and a 200 day simple moving average of $14.20.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.